Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

DUTREBIS

LAMIVUDINE; RALTEGRAVIR POTASSIUM

Standard Dose
150MG;EQ 300MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview DUTREBIS is listed in Drugs@FDA under application 206510 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient LAMIVUDINE; RALTEGRAVIR POTASSIUM Form and strength TABLET;ORAL - 150MG;EQ 300MG BASE Sponsor MERCK SHARP DOHME Submission history Latest submission status date: 2015-02-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview DUTREBIS is listed in Drugs@FDA under application 206510 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LAMIVUDINE; RALTEGRAVIR POTASSIUM Form and strength TABLET;ORAL - 150MG;EQ 300MG BASE Sponsor MERCK SHARP DOHME Submission history Latest submission status date: 2015-02-06 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.